Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia.
about
Acute promyelocytic leukemia: where did we start, where are we now, and the futureAcute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemiaUpdate on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunitiesCentral nervous system involvement of acute promyelocytic leukemia, three case reports.Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.Gemtuzumab ozogamicin: time to resurrect?Relapse of acute promyelocytic leukemia with PML-RARalpha mutant subclones independent of proximate all-trans retinoic acid selection pressureSmall molecule inhibitors in acute myeloid leukemia: from the bench to the clinicTreatment of Acute Promyelocytic Leukemia with AIDA Based Regimen. Update of a Tunisian Single Center StudyMedical applications of leukocyte surface molecules--the CD moleculesFLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.Acute myeloid leukemia stem cells and CD33-targeted immunotherapyTherapeutic research in untreated acute promyelocytic leukemia.The role of gemtuzumab ozogamicin in acute leukaemia therapy.Advances in the treatment for haematological malignancies.Guidelines on the management of acute myeloid leukaemia in adults.New considerations in the design of clinical trials for the treatment of acute leukemia.Molecular Monitoring as a Path to Cure Acute Promyelocytic LeukemiaThe role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients.Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicinEffective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicinTargeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin.Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.How I treat children and adolescents with acute promyelocytic leukaemia.Novel targeted drug therapies for the treatment of childhood acute leukemiaTreatment of acute promyelocytic leukemia during pregnancy.Acute promyelocytic leukemia: what are the treatment options?Acute leukemia in women.Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy.What happened to anti-CD33 therapy for acute myeloid leukemia?Current treatment strategy of acute promyelocytic leukemia.Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin.All-trans retinoic acid in the treatment of pediatric acute promyelocytic leukemia.Current strategies in immunotherapy for acute myeloid leukemia.New therapeutic approaches to acute myeloid leukemia.Management of elderly patients with acute promyelocytic leukemia: progress and problems.Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.Antibody therapy for acute myeloid leukaemia.
P2860
Q26830385-D7C49D2E-4517-4BD6-A120-5710EF30EAF5Q27851694-DCD7D430-9BF3-499B-AAE5-ED106605C601Q27853019-FB1526C9-1DF4-44A0-A28C-E67326C30641Q28071384-713A2A01-1BDB-4EFB-9477-C34074D0687CQ33625750-3E0C754A-85E1-4F23-8BC0-1EDACDACE15BQ33903030-5CB3126C-1E36-4357-8975-76DE8D560500Q34300325-021836E5-070C-4997-818F-70FD3F6D2952Q34471149-80F51C92-3F3A-484C-9DA2-5B5598E323B6Q34817365-B2E4D447-6585-4BEF-AA2F-64FDCC543B46Q35540812-ADA6A485-BD76-4BA4-87E2-7497DDF74A93Q35690889-361178DC-335F-42AA-85BB-99F59CECED7CQ35849209-B52E1951-0D98-45C5-966E-0C0FECB49697Q35980938-91E120F2-E7E4-40D8-9D79-5242B0D8576EQ36058588-D24112BA-5B89-4B57-B4AF-8E0804C355B7Q36103497-36128F5B-E35B-40AE-8123-69F978D9D0FCQ36367816-8E808A58-8297-4CD6-9097-D405A39B33A3Q36429723-0DFC710F-0DC8-421A-9283-8B2BC7C397DDQ36630107-40AAED52-9513-4B53-A1CC-F0009071CA4EQ36641721-48399B12-E1B7-42C9-B79B-BA30261598E2Q36816685-1FEE8C85-B9B1-4394-9214-E7717DD992D2Q36832124-D85383DC-BA7B-4B23-8023-94CF3A556DDCQ36932014-94B33AA1-14EA-4C70-AB7C-633060365018Q36938551-B7DC7009-FD57-4176-813B-4A5487E301C8Q37199950-9A19475A-54E0-4F57-805F-F0EA9997939CQ37271941-17A21381-ACA7-4403-949D-A2D40F1A9238Q37451376-22B7B678-A190-4F04-BF82-EFE37349BFA6Q37477482-04BB5A1B-5875-46F6-B189-5E9EDA9727B9Q37498872-488D9912-E8C8-4971-AD19-C9EA51546311Q37693929-4E43F3C0-B7FE-479A-A341-4C7A0EE78FDBQ37699362-DCAC9377-B6C1-4B93-AB8E-55A8945DF1F3Q37818248-7B744618-9FD7-4D43-B1AD-994F6546696DQ37959880-396A2275-6D32-40EF-9883-71B39DA0AA37Q37971327-F66FF941-0D1A-4552-9C9B-DCF597199909Q38042401-086D166F-098B-4445-8060-34E712003472Q38055497-3EBFC23F-DFD6-4104-BF0B-CE7CCECE9815Q38068967-F1436020-EE00-42C5-9C26-A9819EE27DB4Q38090673-5027102A-B407-4B6D-8046-6C01D6E6EA07Q38108471-0B57479C-E8A2-4828-B3FF-38311E2CC352Q38109541-F9CBDF64-6396-4257-928D-8E3C71783772Q38169814-030C8770-F7C0-489D-8F52-7C7FF9F0358B
P2860
Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Gemtuzumab ozogamicin (Mylotar ...... acute promyelocytic leukemia.
@en
type
label
Gemtuzumab ozogamicin (Mylotar ...... acute promyelocytic leukemia.
@en
prefLabel
Gemtuzumab ozogamicin (Mylotar ...... acute promyelocytic leukemia.
@en
P2093
P50
P1433
P1476
Gemtuzumab ozogamicin (Mylotar ...... acute promyelocytic leukemia.
@en
P2093
Agostino Tafuri
Concetta Micalizzi
Daniela Diverio
Enrico M Pogliani
Erica Finolezzi
Eros Di Bona
Franco Mandelli
Giuseppe Cimino
Mariagrazia Kropp
Nélida I Noguera
P304
P356
10.1182/BLOOD-2004-04-1550
P407
P577
2004-06-08T00:00:00Z